The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Diversity, Equity and Inclusivity in Parkinson's research, 2022Understanding the Progression of Motor and Non-motor Symptoms and Functional Mobility of Māori and Pacific Peoples in New Zealand
Study Rationale: In this study, we will work with two underrepresented groups in Aotearoa, New Zealand, the Māori and Pacific peoples. By better understanding the clinical presentation of Parkinson’s...
-
, 2022Studying the Epidemiology of Parkinson’s Disease in Latin America: Learning from Underrepresented Populations
Study Rationale: Initial evidence has shown that the global distribution of Parkinson’s disease (PD) may vary; however, little is known about the prevalence of PD across large parts of the world. This...
-
Diversity, Equity and Inclusivity in Parkinson's research, 2022Risk Factors for Parkinson’s Disease Among Participants in the Black Women’s Health Study
Study Rationale: Little is known about the incidence, clinical presentation and risk factors for Parkinson’s disease (PD) in Black women, yet the existing evidence suggest that they may have a worse...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Using “Nanobodies” to Prevent Formation of Intracellular Alpha-synuclein Aggregates
Study Rationale: The aggregation of a structurally abnormal form of the protein alpha-synuclein appears to be responsible for the initiation and progression of Parkinson’s disease (PD). In previous...
-
Alpha-synuclein Seed Amplification Assay Program, 2022Development of a Reliable Diagnostic Test for Parkinson’s Disease Using Patient Blood Samples
Study Rationale: Although diagnosis of Parkinson’s disease (PD) is crucial for the success of treatment, especially in the early stages, there are still no biomarkers available for use as a reliable...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Inhibiting Lrrk2 Specifically in the Brain
Study Rationale: Neurodegenerative disorders such as Parkinson’s disease (PD) affect the brain. Some of the drugs designed to treat PD have unwanted side effects in the rest of the body. To minimize...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.